Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2015 by National Institutes of Health Clinical Center (CC).
Recruitment status was:  Active, not recruiting
Sponsor:
Collaborator:
CERN Foundation - Collaborative Ependymoma Research Network
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00826241
First received: January 20, 2009
Last updated: October 21, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Study Completion Date: No date given
  Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)